GO
Loading...

Enter multiple symbols separated by commas

Bayer AG

More

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • June 24- The U.S. Food and Drug Administration said it would discuss the safety and effectiveness of Bayer AG's controversial contraceptive device, Essure, in a public panel meeting after receiving more than 5000 complaints, including those of deaths and pregnancies. The FDA approved the device in November 2002. The FDA said it plans to hold a meeting of the...

  • June 3- German chemicals group BASF SE is considering a potential offer for Syngenta AG, its Swiss rival which has received a $45 billion takeover offer from Monsanto Co, people familiar with the matter said on Wednesday. BASF, Syngenta and Monsanto declined to comment. BASF is also a potential buyer of Syngenta's seed business should Monsanto agree to a deal with...

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...

  • May 7- California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment. The case, which began in 2000 in California state court, centers on a series of settlements in the late 1990 s under...

  • Top California court revives Cipro antitrust case Thursday, 7 May 2015 | 1:12 PM ET

    May 7- California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's antibiotic Cipro off the market in exchange for payment. The ruling marks the first time an appellate court has tackled so-called "pay for delay" deals since a landmark...

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye injection Eylea to grow at a faster rate than it had previously forecast. Sales of Eylea in the United States jumped 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handily beat the average analyst estimate by 20 cents.

  • Regeneron profit rises as Eylea sales jump Thursday, 7 May 2015 | 6:39 AM ET

    May 5- Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea. The U.S. biotechnology company's net profit rose to $76 million, or 66 per share, in the first quarter ended March 31, from $68.3 million, or 61 cents per share, a year earlier. Revenue, including collaboration payments...

  • CARACAS, May 6- Venezuela is investigating whether drug companies including Germany's Merck KGaA and Bayer AG have improperly profited from subsidized foreign exchange amid growing medicine shortages, the country's health minister said. Those firms have received a favorable exchange rate through Venezuela's currency controls to produce or import...

  • April 29- The U.S. Food and Drug Administration said on Wednesday it approved an injection for "double chin" reduction, developed by Kythera Biopharmaceuticals Inc.. Submental, or below the chin, liposuction costs between $2,700 and $5,175, according to the American Society for Dermatologic Surgery. Last year, Kythera regained the rights to market the drug...

  • April 22- DuPont is buying a California- based microbiome discovery company for development of biological crop products, a move that the chemical and crop company hopes will give it an edge in an emerging agricultural market. DuPont's announcement on Wednesday did not disclose how much it is paying for Taxon Biosciences Inc, but said the 15- year-old company...

  • April 22- DuPont is buying a California- based microbiome discovery company for development of biological crop products, a move that the chemical and crop company hopes will give it an edge in an emerging agricultural market. DuPont's announcement on Wednesday did not disclose how much it is paying for Taxon Biosciences Inc, but said the 15- year-old company...

  • UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company. UniQure's gene therapy drug, Glyberan, went on sale last year priced at 1.1 million euros. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford...

  • March 10- The U.S. Food and Drug Administration said it approved United Therapeutics Corp's drug to treat an aggressive form of neuroblastoma, a rare cancer that typically occurs in children below 5 years. Wedbush Securities analyst Liana Moussatos estimated there are about 425 high-risk patients in the United States and 1,275 worldwide.

  • March 9- An injection for double chin reduction developed by Kythera Biopharmaceutical Inc was unanimously backed by an independent panel of experts on Monday, bringing the drug a step closer to approval by the U.S. Food and Drug Administration. The FDA typically accepts the panel's recommendations. The drug is widely expected to win approval by May 13, when the...

  • No safety issues associated with long-term use of ATX-101 have been identified so far, FDA reviewers said on Thursday. An independent panel of experts will meet on Monday to discuss the drug and recommend to the FDA whether it should be approved. Leerink Partners analyst Seamus Fernandez said he expects the drug to be approved by May 13, when the FDA is scheduled...

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • Actavis Plc holds the commercial license to the device, Liletta. Actavis and Medicines360 expect the device to be available for use in the United States by the second quarter of 2015.. The Actavis device will compete in the $1 billion global market for UIDs, said Michael WaterHouse, an analyst at brokerage Morningstar.

  • Bayer R&D budget to increase Thursday, 26 Feb 2015 | 6:00 AM ET
    Bayer R&D budget to increase

    Marijn Dekkers, CEO of Bayer, says the company plans to increase its R&D budget this year, after strong earnings.